Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis

Sakae Fukushima,1 Manami Oishi,2 Hiroya Aso,2 Kifumi Arai,3 Yuuki Sasaki,3 Naohiro Tochikura,1 Susumu Ootsuka,1 Noriyasu Fukuoka,2 Nobuhiro Ooba,2 Norikazu Kikuchi3

1Pharmacy, Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan
2Nihon University School of Pharmacy, Funabashi, Chiba, Japan
3Pharmacy, Nihon University Hospital, Chiyoda-ku, Tokyo, Japan

Correspondence to Sakae Fukushima, Pharmacy, Nihon University Itabashi Hospital, Itabashi-ku 173-8610, Tokyo, Japan; fukushima.sakae@nihon-u.ac.jp

Received 15 February 2021 Accepted 15 June 2021

EHP Statement 4: Clinical Pharmacy Services.

ABSTRACT

Objective To examine the effect of angiotensin II receptor blocker (ARB) treatment on serum potassium level and hyperkalemia risk in a clinical setting with inpatients and outpatients using calcium channel blockers (CCBs) as a reference standard.

Methods The increased risk of hyperkalemia associated with ARB treatment is known, however only a few studies have used an active comparator to examine this risk. In this retrospective study at a 320-bed general hospital in Japan, the hospital information system was used to identify patients with at least one prescription for an ARB (819 patients) or a CCB (1015 patients) who were naïve to these drugs before study initiation. Serum potassium levels before and after ARB treatment were compared. Additionally, the unadjusted and adjusted hazard ratios for the risk of hyperkalemia in the ARB and CCB users were estimated.

Results The serum potassium level was higher in patients receiving ARB treatment (0.05 mEq/L, p=0.02) compared with those on CCB treatment. However, there was no significant association between ARB use and hyperkalemia (adjusted HR 0.91, 95% CI 0.42 to 1.99, p=0.82).

Conclusion The increase in serum potassium level after ARB initiation makes it necessary to monitor serum potassium levels continuously during ARB treatment; however, the risk of hyperkalemia appeared to be similar for ARB and CCB treatments.

INTRODUCTION

Hypertension is a well known risk factor for coronary heart disease, stroke, transient ischemic attack, and diabetes-induced chronic kidney disease.1–6 The incidence and prevalence of hypertension are associated with age,1–6 therefore the number of patients with hypertension will probably increase in the future. Blood pressure control and hypertension management are essential to prevent hypertension-related complications.

Few guidelines for hypertension recommend angiotensin II receptor blockers (ARBs) as the first drug of choice for treating hypertension.1–4 In Japan, ARBs and calcium channel blockers (CCBs) are commonly used as antihypertensive agents in patients of all ages; however, the choice of frequently used drugs varies among countries.5–12 The advantages of ARBs are as follows: reduction in proteinuria13 and protection against the progression of type 2 diabetes induced nephropathy that is independent of their effect on blood pressure.14–16 The influence on heart failure might not be a class effect of ARBs;17 however, the ARB losartan reduced the risk by 32%.15 Losartan reduces uric acid (UA) levels,18–21 but ARBs, including losartan,22 increase the risk of hyperkalemia.21–24 Therefore, monitoring the levels of serum potassium and creatinine is recommended for patients on ARBs.23 Fang and colleagues25 reported a low incidence of hyperkalemia (0.5%) in patients aged 66 years and older using data from the Medicare service claims database and a drug database of the United States. However, a study in Sweden reported a relatively high incidence proportion of hyperkalemia (5.6%) in new users of ARBs.26 Although surveillance of treatment-related hyperkalemia is important,27 only a few studies15,28 have used an active comparator, such as CCBs, to examine the role ARBs have in hyperkalemia. The cumulative incidence rate of hyperkalemia increases from 0.3% to 0.5% in older patients after 6 months of treatment with angiotensin-converting enzyme inhibitors or ARBs.23 Hyperkalemia occurs frequently in the first week after ARB initiation.23 A few randomised controlled trials on ARB with a follow-up period of approximately 3 years indicated that the risk of hyperkalemia increases,15,29 while others have reported no association.30–32 Therefore, it is necessary to elucidate the risk of hyperkalemia in patients with long-term follow-up.

The objective of our retrospective study was to assess the risk of hyperkalemia in response to ARB treatment. The serum levels of potassium and uric acid in response to ARB or CCB treatment were examined in a clinical setting. The findings of this study can provide evidence of the risk of hyperkalemia in patients prescribed ARBs.

METHODS

Setting and population

We used the claims data and laboratory test results obtained from Nihon University Hospital (Tokyo, Japan), a 320-bed general hospital. Inpatients and outpatients with at least one prescription for ARBs or CCBs between 1 October 2014 and 30 June 2018 were included in this study.

Study design

This is a retrospective cohort study. The data for the study were collected from the hospital information system and laboratory test results of the hospital used.
system for individual patients who were prescribed ARBs or CCBs (used as the reference standard). The details collected were patient study ID number (created by a researcher in the hospital); patient demographics (age and sex); dates of hospital visits; diagnoses, as coded using the International Classification of Diseases, 10th edition (ICD-10); laboratory test orders for serum UA, potassium, and creatinine levels; laboratory test values, including the serum UA (mg/dL) and serum potassium (mEq/L) levels; generic names of the drugs; the date of initiation and number of days of administration of the prescribed drugs.

The index date was defined as the day on which the study drug was initiated. The baseline period was defined as the period after the commencement of hospital visits, but before the index date. The observation period was defined as the period from the index date to the last prescription date of each study drug plus the number of prescription days.

All patients who had been prescribed at least one of the study drugs (ie, oral dosage forms of ARBs or CCBs) during the study period were initially included in the study. Patients were excluded if they had received two or more study drugs or if they were concurrently prescribed other antihypertensives on the index date. To mitigate bias created by long-term use, we restricted the study to patients who were naive to the study drugs, based on the record of hospital visits. Hospital researchers identified patients who were initially prescribed ARBs or CCBs between October 2014 and April 2015 based on the data of their hospital visits. Patients with a baseline period shorter than 6 months and/or those who received any antihypertensives during the 6 month period before the index date were excluded from the study.

Outcomes

The primary outcome was the association between hyperkalaemia and ARB treatment compared with the association with CCB treatment. The time to the first event during follow-up was estimated using the Kaplan–Meier plot. Secondary outcomes were the differences in the serum potassium and UA levels before and after ARB or CCB initiation.

Patients with at least one angiotensin II receptor blocker (ARB) or calcium channel blocker prescription (CCB) between October 1, 2014, and June 30, 2018 were initially included. Prescriptions numbered 120,145 (n = 8494) for ARBs and 143,188 (n = 9842) for CCBs.

Patients who received two or more study drugs or who were on concurrent therapy with antihypertensive medications other than the study drugs were excluded (2255 patients on ARBs and 2432 patients on CCBs).

Patients on ARB (n = 6239) or CCB (n = 7408) monotherapy

Patients with prescriptions for any antihypertensive medications within six months before the start of ARBs or CCBs were excluded (5420 patients on ARBs and 6393 patients on CCBs).

Study patients consisted of ARB (n = 819) and CCB (1015) users who were naive to the study medications.

Figure 1  Study flow diagram for patient selection. ARB=angiotensin II receptor blocker; CCB=calcium channel blocker.

Statistical analyses

We assessed the summary statistics of demographic characteristics, comorbidities, co-medications, and laboratory studies of test patients at the baseline period. The number and proportion of patients with these covariates are shown. To compare the baseline characteristics, we calculated the standardised differences among variables. Standardised differences greater than 0.1 were considered meaningful.

We defined the occurrence of hyperkalaemia based on the diagnostic code of hyperkalaemia (E875, ICD-10 code) and the laboratory test order for serum potassium in the claims data. We calculated the period from ARB or CCB initiation to the occurrence of hyperkalaemia. The diagnostic code for hyperkalaemia was used to compare the incidence proportion of hyperkalaemia among patients receiving ARBs with that in those receiving CCBs. The time to the occurrence of hyperkalaemia was depicted using a Kaplan–Meier curve and compared using a log-rank test. We estimated the HR and its 95% CI for the incidence proportion of hyperkalaemia using the Cox proportional hazards model. The incidence proportion of hyperkalaemia in patients receiving CCB treatment was used as the reference standard. Unadjusted and adjusted HRs were calculated in patients without a history of hyperkalaemia. Using the Cox proportional hazards model, we adjusted for age, sex, and known risk factors for hyperkalaemia (renal diseases, heart failure, and diabetes).

The differences in serum levels of potassium and UA during the 3 month period before and after the index date were compared using a paired t-test by drug groups. The mean difference between serum potassium levels before and after the start of ARBs and CCBs was compared using a two-sample t-test after applying the F-test for equality of variance.

To confirm the validity of using the diagnostic code ICD-10 E875 as an outcome, we collected data for all patients with a code of ICD-10 E875 between January 2017 and December 2017, regardless of whether they had used ARBs or CCBs. We used serum potassium level to determine the positive predictive value (PPV) of this code. Hyperkalaemia is defined as a serum
We used these values and the relatively recent data (from 2017) to estimate the PPV and its 95% CI for the condition code of hyperkalaemia.

### RESULTS

#### Baseline characteristics

The number of prescriptions for ARBs and CCBs between 1 October 2014 and 30 June 2018 was 120,145 (n=8494) and 143,188 (n=9842), respectively. Of those, the number of ARB-naive users was 819 (9.6% of ARB users) and the number of CCB-naive users was 1015 (10.4% of CCB users). The flow diagram for the selection of ARB-naive and CCB-naive patients is shown in figure 1.

The mean age±SD of patients treated with ARBs was 67.4±15.5 years, and that of patients treated with CCBs was 68.7±13.1 years. The proportion of men was 63.2% in the ARB group and 56.2% in the CCB group. Some variables were dissimilar between the groups; standardised differences exceeded 0.1 for characteristics, such as sex, diabetes mellitus, and antidiabetic drug use. The characteristics of patients who were naive to the study drugs are listed in table 1.

#### Probability of hyperkalaemia among patients receiving angiotensin II receptor blocker (ARBs) and calcium channel blocker (CCBs).

Survival probability at a time point is the unadjusted probability of not developing hyperkalaemia by that time point. ARB=angiotensin II receptor blocker; CCB=calcium channel blocker.

### Figure 2

Probability of hyperkalaemia among patients receiving angiotensin II receptor blocker (ARBs) and calcium channel blocker (CCBs). Survival probability at a time point is the unadjusted probability of not developing hyperkalaemia by that time point. ARB=angiotensin II receptor blocker; CCB=calcium channel blocker.

### Table 1

Baseline characteristics of patients. Values are numbers (%) unless indicated otherwise.

<table>
<thead>
<tr>
<th>Drug-naive patients</th>
<th>Angiotensin II receptor blockers (n=819)</th>
<th>Calcium channel blockers (n=1015)</th>
<th>Standardised difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years, IQR)</td>
<td>70.0 (61–78)</td>
<td>71.0 (60–79)</td>
<td>0.085</td>
</tr>
<tr>
<td>Male</td>
<td>518 (63.2)</td>
<td>570 (56.2)</td>
<td>−0.145</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>257 (32.2)</td>
<td>884 (46.0)</td>
<td>−0.110</td>
</tr>
<tr>
<td>Heart failure</td>
<td>172 (21.0)</td>
<td>185 (18.2)</td>
<td>−0.070</td>
</tr>
<tr>
<td>Cancer</td>
<td>203 (24.8)</td>
<td>262 (25.8)</td>
<td>0.024</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>133 (16.2)</td>
<td>163 (16.1)</td>
<td>−0.005</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>42 (5.1)</td>
<td>73 (7.2)</td>
<td>0.086</td>
</tr>
<tr>
<td>Renal diseases</td>
<td>76 (9.3)</td>
<td>75 (7.4)</td>
<td>−0.068</td>
</tr>
<tr>
<td>Liver disease</td>
<td>49 (6.0)</td>
<td>45 (4.4)</td>
<td>−0.070</td>
</tr>
<tr>
<td>Hyperkalaemia</td>
<td>20 (2.4)</td>
<td>22 (2.2)</td>
<td>−0.018</td>
</tr>
<tr>
<td>Co-medication</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid-lowering drugs</td>
<td>323 (39.4)</td>
<td>399 (39.3)</td>
<td>−0.003</td>
</tr>
<tr>
<td>Oral anticoagulants</td>
<td>125 (15.3)</td>
<td>177 (17.4)</td>
<td>0.059</td>
</tr>
<tr>
<td>Anti-gout drugs</td>
<td>118 (14.4)</td>
<td>126 (12.4)</td>
<td>−0.059</td>
</tr>
<tr>
<td>Aspirin</td>
<td>338 (41.3)</td>
<td>476 (46.9)</td>
<td>0.114</td>
</tr>
<tr>
<td>Antidiabetic medications</td>
<td>218 (26.6)</td>
<td>217 (21.4)</td>
<td>−0.123</td>
</tr>
</tbody>
</table>
| Lipid-lowering drugs include statins and fibrates. Anti-gout drugs include antihyperuricaemic drugs.

IQR, interquartile range.

### Figure 3

Unadjusted and adjusted hazard ratios for hyperkalaemia in the angiotensin II receptor blocker (ARB) group compared with those in the calcium channel blocker (CCB) group. Multivariate adjusted HR included covariates of age, sex, diabetes, chronic heart failure, renal disease, antidiabetic use, and laboratory test for potassium level.

Results with a p value <0.05 were considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).

### RESULTS

#### Baseline characteristics

The number of prescriptions for ARBs and CCBs between 1 October 2014 and 30 June 2018 was 120,145 (n=8494) and 143,188 (n=9842), respectively. Of those, the number of ARB-naive users was 819 (9.6% of ARB users) and the number of CCB-naive users was 1015 (10.4% of CCB users). The flow diagram for the selection of ARB-naive and CCB-naive patients is shown in figure 1.

The mean age±SD of patients treated with ARBs was 67.4±15.5 years, and that of patients treated with CCBs was 68.7±13.1 years. The proportion of men was 63.2% in the ARB group and 56.2% in the CCB group. Some variables were dissimilar between the groups; standardised differences exceeded 0.1 for characteristics, such as sex, diabetes mellitus, and antidiabetic drug use. The characteristics of patients who were naive to the study drugs are listed in table 1.

#### Probability of hyperkalaemia among patients receiving angiotensin II receptor blocker (ARBs) and calcium channel blocker (CCBs).

Survival probability at a time point is the unadjusted probability of not developing hyperkalaemia by that time point. ARB=angiotensin II receptor blocker; CCB=calcium channel blocker.

### Figure 2

Probability of hyperkalaemia among patients receiving angiotensin II receptor blocker (ARBs) and calcium channel blocker (CCBs). Survival probability at a time point is the unadjusted probability of not developing hyperkalaemia by that time point. ARB=angiotensin II receptor blocker; CCB=calcium channel blocker.

### Figure 3

Unadjusted and adjusted hazard ratios for hyperkalaemia in the angiotensin II receptor blocker (ARB) group compared with those in the calcium channel blocker (CCB) group. Multivariate adjusted HR included covariates of age, sex, diabetes, chronic heart failure, renal disease, antidiabetic use, and laboratory test for potassium level.

Results with a p value <0.05 were considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Losartan use compared with that before losartan use (mean difference −0.39 (1.13, 95% CI 0.01 to 0.03) and CCB (incidence proportion 0.01; 95% CI 0.01 to 0.02) groups. The median time (IQR) from ARB or CCB initiation to the occurrence of hyperkalaemia was 230 (59–343) days for ARBs and 150 (81–208) days for CCBs. Based on the incidence proportion of hyperkalaemia for CCBs as a reference, the difference in the unadjusted HR for ARBs was around 2% in ARB users; however, the proportion may differ between populations. The incidence proportion in previous studies25 26 showed a wide range (0.5–5.6%); the underlying reason needs to be explored in future studies. A network meta-analysis reported that ARB treatment in patients with type 2 diabetes and chronic kidney disease did not significantly increase the risk of hyperkalaemia (OR 1.88, 95% CI 0.86 to 4.12).27 A nationwide cohort study from 122 centres in Brazil reported that ARBs are not associated with a greater risk of hyperkalaemia in patients with stable disease on peritoneal dialysis.37 The differences in some of the covariates (eg, the presence of diabetes, renal disease, and antidiabetic medications; table 1) between patients on ARBs and those on CCBs might have contributed to our findings.

The reduction in the serum levels of UA was low (49.6%; 95% CI 41.0 to 58.2%) for hyperkalaemia between ARB and CCB users was not significant (figure 3).

Changes in serum potassium and serum UA levels after ARB use

The difference in serum potassium levels before and after the index date was 0.03 mEq/L (95% CI −0.004 to 0.07 mEq/L) for ARBs and −0.02 mEq/L (95% CI −0.05 to 0.003 mEq/L) for CCBs. The mean difference between patients receiving ARBs and CCBs was significant with respect to the changes in serum potassium levels before and after the index date (0.05 mEq/L, 95% CI 0.01 to 0.10 mEq/L, p=0.01).

The difference in serum UA levels before and after ARB initiation was not significant for ARBs as a class (−0.08 mg/dL, 95% CI −0.19 to 0.02 mg/dL, p=0.13) or for non-losartan ARBs (−0.04 mg/dL, 95% CI −0.15 to 0.07 mg/dL, p=0.45; figure 4). In contrast, the serum UA level was significantly lower after losartan use compared with that before losartan use (mean difference −0.39 mg/dL, 95% CI −0.76 to −0.03 mg/dL, p=0.04).

PPV of the condition code for hyperkalaemia

The PPV of inpatient and outpatient claims code ICD-10 E875 149 109 for serum potassium ≥5 mEq/L was 85.0% (95% CI 78.3 to 90.7%) and 49.6% (95% CI 41.0 to 58.2%) for serum potassium levels of ≥5 and ≥5.5 mEq/L, respectively.

DISCUSSION

In this retrospective study, we used claims data and hospital laboratory test results to examine whether ARBs influence the serum potassium and UA levels. We found that the risk of hyperkalaemia in patients receiving ARBs was similar to that in those receiving CCBs, although an increase in the serum potassium level was observed in those on ARBs.

The association between hyperkalaemia and ARB use is well known.36 In our study, the use of ARBs led to an insignificant increase in the serum potassium level. This increase was significant compared with that measured after the initiation of CCBs; however, the incidence proportion of hyperkalaemia was not significantly higher in ARB-naive patients compared with that in CCB-naive patients. The incidence proportion of hyperkalaemia was around 2% in ARB users; however, the proportion may differ between populations. The incidence proportion in previous studies25 26 showed a wide range (0.5–5.6%); the underlying reason needs to be explored in future studies. A network meta-analysis reported that ARB treatment in patients with type 2 diabetes and chronic kidney disease did not significantly increase the risk of hyperkalaemia (OR 1.88, 95% CI 0.86 to 4.12).27 A nationwide cohort study from 122 centres in Brazil reported that ARBs are not associated with a greater risk of hyperkalaemia in patients with stable disease on peritoneal dialysis.37 The differences in some of the covariates (eg, the presence of diabetes, renal disease, and antidiabetic medications; table 1) between patients on ARBs and those on CCBs might have contributed to our findings.

The reduction in the serum levels of UA was a class effect of ARBs. Non-losartan ARBs had no significant effect on the UA level, but losartan reduced the UA level; this was consistent with the results of previous studies.21 38–40 The inhibitory effect of losartan on urate transporter 1 is the potential biological mechanism underlying its anti-uricosuric effects in patients with hypertension.41

Strengths

The strength of this study is the high PPV (85.0%) for hyperkalaemia of ≥5 mEq/L when the combination of ICD-10 E875 and laboratory orders for serum potassium level was used. The PPV for the potassium level of ≥5.5 mEq/L was low (49.6%); however, we consider the PPV for the serum potassium level of ≥5.0 mEq/L as critical because, in clinical practice, this is the level at which the risk of renal events begins to increase.12 Additionally, there are only a few studies with ARBs as an active comparator.15 28 The design of randomised controlled trials is different from that of our observational study; however, randomised controlled trials have a high internal, but low external validity, whereas observational studies in clinical settings have low internal and high external validity.43

Limitations

Our study had some potential limitations. First, it was conducted in a single centre in Japan; this might restrict the generalisability of our findings, including those for PPVs. Second, the HR for hyperkalaemia might have been unstable because of the wide 95% CI, which was a result of the small number of patients. Third, we were unable to examine the dose–response relationship because we had no information on the dosage of study drugs.

The serum potassium level was higher after the initiation of ARBs compared with that after the initiation of CCBs; however, a comparison of the incidence proportion of hyperkalaemia between patients receiving ARBs and those receiving CCBs

### Table 2: Positive predictive value of the diagnostic code for hyperkalaemia in 2017

<table>
<thead>
<tr>
<th>Non-laboratory parameters for defining hyperkalaemia</th>
<th>Total</th>
<th>Serum potassium ≥5 mEq/L</th>
<th>Serum potassium ≥5.5 mEq/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10 E875</td>
<td>149</td>
<td>109 (72.2, 66.0 to 80.3)</td>
<td>64 (43.0, 35.0 to 50.9)</td>
</tr>
<tr>
<td>ICD-10 E875 + laboratory test order for serum potassium</td>
<td>129</td>
<td>109 (85.0, 78.3 to 90.7)</td>
<td>64 (49.6, 41.0 to 58.2)</td>
</tr>
</tbody>
</table>
revealed no association between ARB use and hyperkalaemia. Therefore, it may be important to assess the potassium level and renal function at the start of ARB use. To evaluate the risk of hyperkalaemia, further studies using a higher number of patients in multiple clinical centres are needed.

What this paper adds

What is already known on this subject

► Angiotensin II receptor blockers (ARBs) are drugs of choice for the treatment of hypertension.

► ARBs are known to increase the risk of hyperkalaemia.

► ARB losartan has a beneficial effect of reducing uric acid (UA) level.

What this study adds

► The risk of hyperkalaemia in patients receiving ARBs was similar to that in patients receiving calcium channel blockers.

► The use of ARBs led to a non-significant increase in serum potassium levels, although this increase was significant compared with that measured after the initiation of CCBs.

► ARBs other than losartan did not reduce the UA level, indicating that it was not a class effect of ARBs.

Contributors All authors contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

Funding This was partially supported by a Nihon University Chairman of the Board of Trustees Grant.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the ethics committees of both Nihon University Hospital (no. 201806002) and Nihon University School of Pharmacy (no. 18-009). Both ethics committees waived the need for informed consent from patients, as the study data were fully anonymised.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. fukushima.sakae@nihon-u.ac.jp

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

References


Original research


